全球领先的移植中心正在通过检测血管活性抗体，改变对排斥反应和移植物失功的评估与管理方式
超越HLA：解锁移植免疫风险的隐藏维度——AT1R抗体检测
在肾、心、肝、肺移植以及干细胞移植后，高达16% 的急性排斥反应病例无法通过传统的HLA donor-specific antibody (HLA-DSA)检测找到原因。这些病例通常表现为严重的血管性排斥、恶性高血压和加速性移植物血管病变，导致移植物功能迅速丧失。
根源在于：血管活性非HLA抗体——抗血管紧张素II 1型受体抗体（AT1R-Ab）。
什么是AT1R抗体？
什么是AT1R抗体？
AT1R抗体是针对人体内一种关键受体——血管紧张素II 1型受体（AT1R）的自身抗体。这种受体的异常激活会导致血管收缩、炎症和组织纤维化。在移植受者中，高水平的AT1R抗体已被证实是独立于HLA-DSA的、强有力的移植物失功风险因子。
坚实的临床证据
坚实的临床证据：来自全球多家移植中心的研究
1. 肾移植：预测排斥与移植物丢失的关键指标
•Dragun et al. (NEJM, 2005)：首次在16例发生严重血管性排斥但HLA-DSA阴性的肾移植受者中发现了AT1R抗体。
•Reinsmoen & Dragun (Transplantation, 2010)：证实AT1R抗体与抗体介导的排斥反应（AMR）强烈相关，为HLA-DSA阴性患者的免疫风险提供了关键信息。
•Terasaki et al. (Am J Transplant, 2013)：对351名肾移植受者的研究表明，同时存在AT1R抗体和HLA-DSA的患者，其移植物存活率最低，风险具有协同效应。AT1R抗体是移植物失败的独立预测因子（HR: 5.4-6.6）。
2. 心脏移植：与移植物血管病变（CAV）和排斥反应紧密相连
•Hetzer et al. (Transplantation, 2012)：心脏移植前高水平的AT1R抗体与早期微血管病变、AMR和细胞性排斥反应（CMR） 的发生率显著增高有关。
•Kobashigawa & Reinsmoen (Transplantation, 2014)：数据显示，新发HLA-DSA和高AT1R抗体水平并存时，发生排斥反应的风险比（HR）高达10.5。
3. 肝、肺与干细胞移植：风险无处不在
•肝移植：AT1R抗体与HLA-DSA共存时，死亡风险增加；新发AT1R抗体与排斥反应和纤维化进展相关。
•肺移植：移植前高水平的AT1R抗体对无AMR生存期有负面影响。
•干细胞移植：AT1R抗体水平与慢性移植物抗宿主病（cGVHD） 和急性GVHD的发生显著相关。
4.手部移植
•Banasik等人研究了5例手部移植患者中抗AT1R和抗ETAR抗体水平（42）。在一个反复发生急性排斥反应的患者中，发现抗AT1R和抗ETAR抗体水平均显著升高。
为什么必须在常规检测中加入AT1R抗体筛查？
1.填补诊断空白：为HLA-DSA阴性的排斥反应提供免疫学解释。
2.精准风险评估：在移植前识别高风险患者，实现免疫风险的分层管理。
3.指导个体化治疗：帮助医生制定更积极或更具针对性的免疫抑制方案。
4.预测长期预后：与移植物血管病变、纤维化和移植物丢失密切相关。
“评估AT1R抗体状态与HLA-DSA，能为受者的免疫风险提供额外信息。”——Prof. N. Reinsmoen (Cedars-Sinai)
解决方案
解决方案：CE认证的AT1R抗体ELISA检测试剂盒
我们提供全球领先的、CE认证的AT1R抗体ELISA检测试剂盒，适用于血清或血浆样本的常规筛查。
•高特异性与灵敏度：为您提供可靠、准确的检测结果。
•标准化操作：便于实验室整合到现有的抗体检测流程中。
•为临床决策赋能：将强大的科研证据转化为日常临床实践工具。
适用于：肾移植、心脏移植、肝移植、肺移植、干细胞移植及手移植后的免疫监测。
如需更多信息，请与荣志海达客服专员联系。
底部免责声明：
底部免责声明：
本产品仅用于科研用途（For Research Use Only），不用于临床诊断（Not for Use in Diagnostic Procedures）。
01
参考文献
1.D Dragun, DN Müller, JH Bräsen, L Fritsche, M Nieminen-Kelhä, R Dechend, U Kintscher, B Rudolph, J Hoebeke, D Eckert, I Mazak, R Plehm, C Schönemann, T Unger, K Budde, HH Neumayer, FC Luft, G Wallukat. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 352(6), 558-569 (2005)
2.NL Reinsmoen, CH Lai, H Heidecke, M Haas, K Cao, G Ong, M Naim, Q Wang, J Mirocha, J Kahwaji, AA Vo, SC Jordan, D Dragun. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation. 90(12), 1473-1477 (2010)
3.M Taniguchi, LM Rebellato, J Cai, J Hopfield, KP Briley, CE Haisch, PG Catrou, P Bolin, K Parker, WT Kendrick, SA Kendrick, RC Harland, PI Terasaki. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant. 13(10), 2577- 2589 (2013)
4.M Giral, Y Foucher, A Dufay, JP Van Huyen, K Renaudin, A Moreau, A Philippe, B Hegner, R Dechend, H Heidecke, S Brouard, A Cesbron, S Castagnet, A Devys, JP Soulillou, D Dragun. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant. 13(10), 2567-2576 (2013)
5.AJ Gareau, C Wiebe, D Pochinco, IW Gibson, J Ho, DN Rush, PW Nickerson. Pre-transplant AT1R antibodies correlate with early allograft rejection. Transpl Immunol. 46, 29-35 (2017)
6.MA Lim, M Palmer, J Trofe-Clark, RD Bloom, A Jackson, MC Philogene, M Kamoun. Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies. Hum Immunol. 78(4), 350-356 (2017)
7.I Guzzo, F Morolli, FD Camassei, A Piazza, E Poggi, L Dello Strologo. Acute kidney transplant rejection mediated by angiotensin II type 1 receptor antibodies in a pediatric hyperimmune patient. Pediatr Nephrol. 32(1), 185-188 (2017)
8.MC Philogene, S Bagnasco, ES Kraus, RA Montgomery, D Dragun, MS Leffell, AA Zachary, AM Jackson. Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies. Transplantation. 101(3), 608-615 (2017)
9.S Iesari, Q Lai, E Favi, F Pisani. Bortezomib- Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti- HLA and Anti-AT1R Antibodies after Kidney Transplantation. Yonsei Med J. 58(3), 679– 681 (2017)
10.J Lee, KH Huh, Y Park, BG Park, J Yang, JC Jeong, J Lee, JB Park, JH Cho, S Lee, H Ro, SY Han, MS Kim, YS Kim, SJ Kim, CD Kim, W Chung, SB Park, C Ahn, KNOW-KT Study Group. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal Transplantation. Nephrol Dial Transplant. 32(7), 1244-1250 (2017)
11.MH Pearl, RK Leuchter, EF Reed, Q Zhang, RB Ettenger, EW Tsai. Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies. Pediatr Nephrol. 30(8), 1371-1374 (2015)
12.H Lee, Ji Kim, IS Moon, BH Chung, CW Yang, Y Kim, K Han, EJ Oh. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection. Ann Lab Med. 35(3), 314-320 (2015)
13.J Lee, Y Park, BS Kim, JG Lee, HJ Kim, YS Kim, KH Huh. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal Transplantation. Transplant Proc. 47(3), 649-652 (2015)
14.A Jobert, N Rao, S Deayton, GD Bennett, J Brealey, J Nolan, RP Carroll, D Dragun, PT Coates. Angiotensin II type 1 receptor antibody precipitating acute vascular rejection in kidney Transplantation. Nephrology (Carlton). 20 Suppl 1, 10-12 (2015)
15.A Fuss, CM Hope, S Deayton, GD Bennett, R Holdsworth, RP Carroll, PT Coates. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies. Nephrology (Carlton). 20(7), 467-473 (2015)
16.JW In, H Park, EY Rho, S Shin, KU Park, MH Park, EY Song. Anti-angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-donor-specific antibody. Transplant Proc. 46(10), 3371- 3374 (2014)
17.B Kranz, R Kelsch, E Kuwertz-Bröking, V Bröcker, HH Wolters, M Konrad. Acute antibody-mediated rejection in paediatric renal transplant recipients. Pediatr Nephrol. 26(7), 1149-1156 (2011)
18.R Kelsch, AS Everding, E Kuwertz-Bröking, E Brand, BM Spriewald, W Sibrowski, M Konrad, D Dragun. Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II. Transplantation. 92(10), 57-59 (2011)
19.J Malheiro, S Tafulo, L Dias, S Martins, I Fonseca, I Beirão, A Castro-Henriques, A Cabrita. Deleterious Effect of Anti- Angiotensin II Type 1 Receptor Antibodies Detected Pretransplant on Kidney Graft Outcomes is Both Proper and Synergistic with donor-specific anti-HLA antibodies. Nephrology (Carlton). (2018)
20.M Banasik, M Boratyńska, K Kościelska- Kasprzak, O Mazanowska, D Bartoszek, M Zabińska, M Myszka, B Nowakowska, A Hałoń, P Szyber, D Patrzałek, M Klinger. Long-term follow-up of non-HLA and anti-HLA antibodies: incidence and importance in renal Transplantation. Transplant Proc. 45(4), 1462-1465 (2013)
21.MH Pearl, Q Zhang, MF Palma Diaz, J Grotts, M Rossetti, D Elashoff, DW Gjertson, P Weng, EF Reed, E Tsai Chambers. Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney Transplantation. Kidney Int. 93(1), 260-269 (2018)
22.E Cuevas, JM Arreola-Guerra, EA Hernández-Méndez, I Salcedo, N Castelán, NO Uribe-Uribe, M Vilatobá, AG Contreras- Saldívar, AI Sánchez-Cedillo, JB Ramírez, D de Rungs, J Granados, LE Morales- Buenrostro, J Alberú. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies. Nephrol Dial Transplant. 31(10), 1738-1745 (2016)
23.MA Mujtaba, AA Sharfuddin, BL Book, WC Goggins, AA Khalil, DP Mishler, JA Fridell, MS Yaqub, TE Taber. Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence. Clin Transplant. 29(7), 606-611 (2015)
24.M Banasik, M Boratyńska, K Kościelska- Kasprzak, D Kamińska, S Zmonarski, O Mazanowska, M Krajewska, D Bartoszek, M Zabińska, M Myszka, M Kamińska, A Hałoń, T Dawiskiba, P Szyber, A Sas, M Klinger. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss. Transplant Proc. 46(8), 2618-2621 (2014)
25.M Banasik, M Boratyńska, K Kościelska- Kasprzak, D Kamińska, D Bartoszek, M Zabińska, M Myszka, S Zmonarski, M Protasiewicz, B Nowakowska, A Hałoń, P Chudoba, M Klinger. The influence of non- HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes. Transpl Int. 27(10), 1029-1038 (2014)
26.A Fichtner, C Süsal, C Schröder, B Höcker, S Rieger, R Waldherr, JH Westhoff, A Sander, D Dragun, B Tönshoff. Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients. Nephrol Dial Transplant. (2018)
27.S Anwar, DS Larson, N Naimi, M Ashraf, N Culiberk, H Liapis, C Wei, J Reiser, DC Brennan. A case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring. Front Med (Lausanne) 2, 13 (2015)
28.MC Philogene, S Zhou, BE Lonze, S Bagnasco, S Alasfar, RA Montgomery, E Kraus, AM Jackson, MS Leffell, AA Zachary. Pre-transplant Screening for Non-HLA Antibodies: Who Should Be Tested? Hum Immunol. (2018)
29.X Zhang, NL Reinsmoen. Impact of Non-Human Leukocyte Antigen- Specific Antibodies in Kidney and Heart Transplantation. Front Immunol. 8, 434 (2017)
30.NL Reinsmoen. Immunological Risk Stratification by Assessing Both the HLA and Non-HLA-Specific Antibodies: Time to Include Testing for Non-HLA Antibodies in the Routine Clinical Antibody Analysis Profile? Transplantation 101(1), 23-25 (2017)
31.A Loupy, M Haas, K Solez, L Racusen, D Glotz, D Seron, BJ Nankivell, RB Colvin, M Afrouzian, E Akalin, N Alachkar, S Bagnasco, JU Becker, L Cornell, C Drachenberg, D Dragun, H de Kort, IW Gibson, ES Kraus, C Lefaucheur, C Legendre, H Liapis, T Muthukumar, V Nickeleit, B Orandi, W Park, M Rabant, P Randhawa, EF Reed, C Roufosse, SV Seshan, B Sis, HK Singh, C Schinstock, A Tambur, A Zeevi, M Mengel. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. Am J Transplant. 17(1), 28-41 (2017)
32.G Riemekasten, A Philippe, M Näther, T Slowinski, DN Müller, H Heidecke, M Matucci- Cerinic, L Czirják, I Lukitsch, MO Becker, A Kill, JM van Laar, R Catar, FC Luft, GR Burmester, B Hegner, D Dragun. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis. 70(3), 530-536 (2011)
33.NE Hiemann, R Meyer, E Wellnhofer, C Schoenemann, H Heidecke, N Lachmann, R Hetzer, D Dragun. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart Transplantation. Transplantation 94(9), 919-924 (2012)
34.NL Reinsmoen, CH Lai, J Mirocha, K Cao, G Ong, M Naim, Q Wang, M Haas, M Rafiei, L Czer, J Patel, J Kobashigawa. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation 97(5), 595-601 (2014)
35.P Bruneval, A Angelini, D Miller, L Potena, A Loupy, A Zeevi, EF Reed, D Dragun, NL Reinsmoen, RN Smith, L West, S Tebutt, T Thum, M Haas, M Mengel, P Revelo, M Fedrigo, JP Duong Van Huyen, GJ Berry. The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions. Am J Transplantation 17, 42–53 (2017)
36.X Zhang, J Mirocha, T Aintablian, S Dimbil, J Moriguchi, F Arabia, JA Kobashigawa, NL Reinsmoen. Revealing a new mode of sensitization induced by mechanical circulatory support devices: Impact of anti- AT1R antibodies. Clin Transplant. (2018)
37.JG O’Leary, AJ Demetris, A Philippe, R Freema, J Cai, H Heidecke, C Smith, B Hart, LW Jennings, R Catar, M Everly, GB Klintmalm, D Dragun. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. Transplantation 101(10), 2399-2409 (2017)
38.H Ohe, Y Uchida, A Yoshizawa, H Hirao, M Taniguchi, E Maruya, K Yurugi, R Hishida, T Maekawa, S Uemoto, PI Terasaki. Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation 98(10), 1105-1111 (2014)
39.NL Reinsmoen, J Mirocha, CR Ensor, M Marrari, G Chaux, DJ Levine, X Zhang, A Zeevi. A 3-Center Study Reveals New Insights Into the Impact of Non-HLA Antibodies on Lung Transplantation Outcome. Transplantation 101(6), 1215- 1221 (2017)
40.A Chiron, JD Bouaziz, M Carmagnat, R Peffault de Latour R, A Lafaurie-Bergeron, M Robin, A Xhaard, A Toubert, D Charron, N Guigue, G Socié, D Bengoufa. Anti- Angiotensin type 1 receptor antibodies in chronic graft-versus-host disease. Transplantation 98(4), 470-474 (2014)
41.M Taniguchi, K Gendzekhadze, JH Lee, D Senitzer. Anti-angiotensin II Type-1 receptor antibodies in failed chimerism after hematopoietic stem cell Transplantation. ASHI (2017)
42. M Banasik, J Jabłecki, M Boratyńska, D Kamińska, K Kościelska-Kasprzak, D Bartoszek, A Chełmoński, A Hałoń, W Baran, M Klinger. Humoral immunity in hand transplantation: anti-HLA and non-HLA response. Hum Immunol. 75(8), 859-862 (2014)